Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism.
Nelson B WattsJohn P BilezikianHenry G BoneBart Lyman ClarkeDouglas DenhamMichael A LevineMichael MannstadtMunro PeacockJeffrey H RothmanTamara J VokesMark L WarrenShaoming YinNicole SherryDolores M ShobackPublished in: Journal of the Endocrine Society (2023)
6 years of rhPTH(1-84) treatment was associated with sustained improvements in biochemical parameters, a reduction in the percentage of patients with hypercalciuria, stable renal function, and decreased supplement requirements. rhPTH(1-84) was well tolerated; no new safety signals were identified.